{"schema_version":"secwatch.filing_event.v1","accession":"0001214659-24-009785","form_type":"8-K","ticker":"ALZN","cik":"0001677077","company_name":"Alzamend Neuro, Inc.","filed_at":"2024-05-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.539579+00:00","generated_at":"2026-06-01T09:46:58.305882+00:00","sec_items":["7.01","3.01","9.01"],"event_type":"regulatory","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Alzamend Neuro gets Nasdaq extension to meet $2.5M equity rule by Sept 23, 2024","bullets":["Nasdaq Hearings Panel granted continued listing on Capital Market, subject to compliance with Listing Rule 5550(b)(1).","Company must demonstrate stockholder equity of at least $2.5 million on or before September 23, 2024.","Appeal hearing held May 9, 2024; panel decision received May 21, 2024.","CEO Stephan Jackman stated company is implementing its compliance plan."],"urls":{"canonical":"https://secwatch.observer/filing/0001214659-24-009785","json":"https://secwatch.observer/filing/0001214659-24-009785.json","markdown":"https://secwatch.observer/filing/0001214659-24-009785.md","text":"https://secwatch.observer/filing/0001214659-24-009785.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1677077/000121465924009785/0001214659-24-009785-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1677077/000121465924009785/p5212408k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T09:46:58.305882+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}